Dissecting the Roles of Lipids in Preeclampsia

Yang, Yu; Wang, Yixiao; Lv, Yan; Ding, Hongjuan

doi:10.3390/metabo12070590

Cited by 14 publications

(10 citation statements)

References 69 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There was an overall pronounced increase in lipid concentrations in cases with adverse outcomes. Similar to significant alterations in metabolites during an uncomplicated pregnancy (Orczyk-Pawilowicz et al, 2016 ), there are also complex changes in lipids, and lipid abnormalities which are well-established risk factor for the development of PreE (Mitro et al, 2021 ; Yang et al, 2022 ). Alterations in maternal blood and placental lipidome have been implicated in the pathogenesis of severe PreE and adverse outcomes (Baig et al, 2013 ; He et al, 2021 ).…”

Section: Discussionmentioning

confidence: 99%

Metabolomic prediction of severe maternal and newborn complications in preeclampsia

Idler,

Turkoglu,

Yilmaz

et al. 2024

Metabolomics

View full text Add to dashboard Cite

Introduction Preeclampsia (PreE) remains a major source of maternal and newborn complications. Prenatal prediction of these complications could significantly improve pregnancy management. Objectives Using metabolomic analysis we investigated the prenatal prediction of maternal and newborn complications in early and late PreE and investigated the pathogenesis of such complications. Methods Serum samples from 76 cases of PreE (36 early-onset and 40 late-onset), and 40 unaffected controls were collected. Direct Injection Liquid Chromatography–Mass Spectrometry combined with Nuclear Magnetic Resonance (NMR) spectroscopy was performed. Logistic regression analysis was used to generate models for prediction of adverse maternal and neonatal outcomes in patients with PreE. Metabolite set enrichment analysis (MSEA) was used to identify the most dysregulated metabolites and pathways in PreE. Results Forty-three metabolites were significantly altered (p < 0.05) in PreE cases with maternal complications and 162 metabolites were altered in PreE cases with newborn adverse outcomes. The top metabolite prediction model achieved an area under the receiver operating characteristic curve (AUC) = 0.806 (0.660–0.952) for predicting adverse maternal outcomes in early-onset PreE, while the AUC for late-onset PreE was 0.843 (0.712–0.974). For the prediction of adverse newborn outcomes, regression models achieved an AUC = 0.828 (0.674–0.982) in early-onset PreE and 0.911 (0.828–0.994) in late-onset PreE. Profound alterations of lipid metabolism were associated with adverse outcomes. Conclusion Prenatal metabolomic markers achieved robust prediction, superior to conventional markers for the prediction of adverse maternal and newborn outcomes in patients with PreE. We report for the first-time the prediction and metabolomic basis of adverse maternal and newborn outcomes in patients with PreE.

show abstract

Section: Discussionmentioning

confidence: 99%

Metabolomic prediction of severe maternal and newborn complications in preeclampsia

Idler,

Turkoglu,

Yilmaz

et al. 2024

Metabolomics

View full text Add to dashboard Cite

show abstract

“…Polyunsaturated fatty acids, derived from maternal nutrition, may alter epigenetic gene regulation by the transcriptional induction or repression of key genes during ontogeny [ 9 , 10 ] that influence progeny health over the life course. Lipids are multifunctional and ubiquitous metabolites and are often essential for various cell and organism functions [ 11 ]. Fatty acids serve as substrates to produce energy, and specific fatty acids trigger various signaling pathways for cellular function [ 12 ].…”

Section: Maternal and Child Health And Developmental Programmingmentioning

confidence: 99%

“…Preeclampsia, an autoimmune gestational disease (in 3–5% of all pregnancies), is typified by varying degrees of placental malperfusion and antiangiogenic factor release into the bloodstream that result in maternal vascular endothelial injury, elevated blood pressure [ 11 ] and renal failure [ 53 , 54 ]. Preeclampsia is routinely diagnosed, and women are asymptomatic but have hypertension [ 55 ].…”

Section: Gestational Diabetes Preeclampsia Polycystic Ovary Syndrome ...mentioning

confidence: 99%

“…Upon diagnosis, there is no cure until the mother gives birth. Lipid metabolite anomalies and altered lipid concentrations present risks for preeclampsia [ 11 , 57 ], as lipid and lipoprotein accumulation in the arterial wall may cause atheroma plaques to form, which may lead to atherosclerosis [ 58 , 59 ].…”

Section: Gestational Diabetes Preeclampsia Polycystic Ovary Syndrome ...mentioning

confidence: 99%

See 1 more Smart Citation

Maternal and Child Health, Non-Communicable Diseases and Metabolites

Cerf

2023

Metabolites

View full text Add to dashboard Cite

Mothers influence the health and disease trajectories of their children, particularly during the critical developmental windows of fetal and neonatal life reflecting the gestational–fetal and lactational–neonatal phases. As children grow and develop, they are exposed to various stimuli and insults, such as metabolites, that shape their physiology and metabolism to impact their health. Non-communicable diseases, such as diabetes, cardiovascular disease, cancer and mental illness, have high global prevalence and are increasing in incidence. Non-communicable diseases often overlap with maternal and child health. The maternal milieu shapes progeny outcomes, and some diseases, such as gestational diabetes and preeclampsia, have gestational origins. Metabolite aberrations occur from diets and physiological changes. Differential metabolite profiles can predict the onset of non-communicable diseases and therefore inform prevention and/or better treatment. In mothers and children, understanding the metabolite influence on health and disease can provide insights for maintaining maternal physiology and sustaining optimal progeny health over the life course. The role and interplay of metabolites on physiological systems and signaling pathways in shaping health and disease present opportunities for biomarker discovery and identifying novel therapeutic agents, particularly in the context of maternal and child health, and non-communicable diseases.

show abstract

“…This test would identify pregnancies at higher risk of preeclampsia even in a population of pregnant women with no risk factors. Therefore, we can identify women requiring more intensive health surveillance, starting from the first weeks of pregnancy [ 29 ], with the chance to adopt prophylactic strategies, such as the daily intake of low-dose acetylsalicylic acid, which are more successful if initiated before the end of the placentation process, that is abnormal in the case of PE [ 30 , 31 , 32 , 33 ]. As a secondary objective, we evaluated the test’s ability to predict the risk of developing adverse obstetric outcomes such as fetal growth restriction (FGR or IUGR), intrauterine fetal death (IUFD), gestational hypertension, HELLP syndrome, placental abruption, and preterm birth.…”

Section: Introductionmentioning

confidence: 99%

Results of a Five-Year Experience in First Trimester Preeclampsia Screening

Capriglione

Gulino²,

Latella³

et al. 2022

JCM

View full text Add to dashboard Cite

Background and Objectives: The study aimed to evaluate the ability defining the risk of developing preeclampsia by a screening test carried out in the first trimester (between 11 + 0 and 13 + 6 weeks of gestational age), in order to identify high-risk women requiring more intensive health surveillance. The secondary objective was to evaluate the ability of this test to predict the risk of adverse obstetric outcomes such as fetal growth restriction, intrauterine fetal death, gestational hypertension, HELLP syndrome, placental abruption, and preterm birth. Materials and Methods: This was a single-center study, conducted at the Operative Unit of Obstetrics of the State Hospital of the Republic of San Marino. Medical history was collected at the time of enrolment in writing. Subsequently, obstetric outcomes were collected for each enrolled woman, through the analysis of medical records. Results: From October 2014 to May 2019, 589 pregnant women were recruited, of whom, 474 (80.5%) were included in the “low-risk” group, and 115 (19.5%) in the “high-risk” group. At the time of analysis of this population, the obstetric outcomes were available for 498 women (84.5%), while 91 cases (15.5%) were current pregnancies. The PI of the uterine arteries was not significantly different between the two study groups. Otherwise, a significant difference was highlighted for MAP, which is higher in the case of pregnancies at high risk based on the risk factors only, and for PAPP-A, higher in the case of low-risk pregnancies. Regarding the percentage of fetal DNA, according to the most recent literature data, in our series, we report a statistically significant difference of the average between the low and high-risk groups. Conclusions: In our study, we demonstrate that the multiparametric screening test for early PE performed well in identifying women at high risk of early PE, which certainly has the most severe maternal–fetal outcomes. The data reported that ASA intake at low doses is significantly higher in the population with high-risk tests for both early PE and late PE suggest once again that anamnestic evaluation plays an essential role in women’s screening.

show abstract

Dissecting the Roles of Lipids in Preeclampsia

Cited by 14 publications

References 69 publications

Metabolomic prediction of severe maternal and newborn complications in preeclampsia

Metabolomic prediction of severe maternal and newborn complications in preeclampsia

Maternal and Child Health, Non-Communicable Diseases and Metabolites

Results of a Five-Year Experience in First Trimester Preeclampsia Screening

Contact Info

Product

Resources

About